NFlection Therapeutics is a Wayne, Pa.-based biopharma focused on discovery and development of targeted therapies for rare RASopathy disorders driven by aberrant activation of the Ras/Raf/MEK/ERK pathway. The company is developing first-in-class soft MEK inhibitors formulated as topical treatments to mitigate or treat cutaneous neurofibromas in neurofibromatosis type 1, congenital birthmarks, and immunosuppressant-mediated squamous cell carcinoma. Its topical MEK inhibitors are designed to degrade rapidly in circulation to avoid systemic side effects. NFlection announced initiation of the first clinical trial of its lead product, NFX-179 Gel, following submission of an Investigational New Drug application to the U.S. FDA. The Phase 2a study is a randomized, double-blind, placebo-controlled safety, tolerability and pharmacokinetic/pharmacodynamic trial of three concentrations of NFX-179 Gel versus vehicle in 48 adult patients with cutaneous neurofibromatosis type-1, to be conducted at five U.S. investigational centers. The company is led by president & CEO Christopher Powala and recently closed a $20M Series A financing.

Total raised

$20M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2020